Augusto Villanueva

41.3k total citations · 14 hit papers
147 papers, 23.2k citations indexed

About

Augusto Villanueva is a scholar working on Hepatology, Cancer Research and Molecular Biology. According to data from OpenAlex, Augusto Villanueva has authored 147 papers receiving a total of 23.2k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Hepatology, 54 papers in Cancer Research and 47 papers in Molecular Biology. Recurrent topics in Augusto Villanueva's work include Hepatocellular Carcinoma Treatment and Prognosis (72 papers), Cancer Genomics and Diagnostics (36 papers) and Liver Disease Diagnosis and Treatment (32 papers). Augusto Villanueva is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (72 papers), Cancer Genomics and Diagnostics (36 papers) and Liver Disease Diagnosis and Treatment (32 papers). Augusto Villanueva collaborates with scholars based in United States, Spain and Germany. Augusto Villanueva's co-authors include Josep M. Llovet, Jessica Zucman‐Rossi, Richard S. Finn, Scott L. Friedman, Sasan Roayaie, Kazuhiko Koike, Robin Kate Kelley, Riccardo Lencioni, Amit G. Singal and Eli Pikarsky and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Augusto Villanueva

143 papers receiving 23.0k citations

Hit Papers

Hepatocellular carcinoma 2008 2026 2014 2020 2021 2019 2008 2015 2009 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Hepatocellular carcinoma
    2021 4.1k citations Josep M. Llovet, Robin Kate Kelley et al. Nature Reviews Disease Primers profile →
  2. Hepatocellular Carcinoma
    2019 3.2k citations Augusto Villanueva profile →
  3. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    2008 1.1k citations Philippa Newell, Augusto Villanueva et al. Molecular Cancer Therapeutics profile →
  4. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
    2015 945 citations Jessica Zucman‐Rossi, Augusto Villanueva et al. Gastroenterology profile →
  5. Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma
    2009 872 citations Yujin Hoshida, Sebastian Nijman et al. Cancer Research profile →
  6. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
    2016 864 citations Daniela Sia, Augusto Villanueva et al. Gastroenterology profile →
  7. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
    2017 632 citations Daniela Sia, Carlos Villacorta-Martín et al. Gastroenterology profile →
  8. Tumour evolution in hepatocellular carcinoma
    2019 584 citations Amanda J. Craig, Johann von Felden et al. profile →
  9. Advances in targeted therapies for hepatocellular carcinoma in the genomic era
    2015 495 citations Josep M. Llovet, Augusto Villanueva et al. profile →
  10. Targeted Therapies for Hepatocellular Carcinoma
    2011 378 citations Augusto Villanueva, Josep M. Llovet Gastroenterology profile →
  11. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
    2022 269 citations Josep M. Llovet, Robin Kate Kelley et al. profile →
  12. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
    2020 240 citations Josep M. Llovet, Augusto Villanueva et al. Hepatology profile →
  13. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)
    2021 165 citations Philipp K. Haber, Parissa Tabrizian et al. Gastroenterology profile →
  14. Biomarkers for immunotherapy of hepatocellular carcinoma
    2023 109 citations Augusto Villanueva et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Augusto Villanueva United States 61 10.2k 8.8k 7.2k 5.4k 5.0k 147 23.2k
Jessica Zucman‐Rossi France 82 13.9k 1.4× 9.0k 1.0× 7.8k 1.1× 7.2k 1.3× 6.4k 1.3× 322 31.8k
Ann‐Lii Cheng Taiwan 80 7.9k 0.8× 10.1k 1.1× 4.6k 0.6× 10.4k 1.9× 5.1k 1.0× 794 28.2k
Lewis R. Roberts United States 76 9.4k 0.9× 13.3k 1.5× 6.6k 0.9× 6.3k 1.2× 9.7k 1.9× 428 29.4k
Irene Oi‐Lin Ng Hong Kong 97 15.4k 1.5× 9.3k 1.1× 9.4k 1.3× 7.9k 1.5× 5.7k 1.1× 483 31.4k
Alejandro Forner Spain 35 4.5k 0.4× 17.4k 2.0× 5.0k 0.7× 4.5k 0.8× 10.1k 2.0× 120 25.1k
Zhao–You Tang China 63 6.5k 0.6× 5.2k 0.6× 5.2k 0.7× 4.1k 0.8× 2.8k 0.6× 209 14.8k
Sheung Tat Fan Hong Kong 79 5.8k 0.6× 9.6k 1.1× 3.5k 0.5× 5.5k 1.0× 5.1k 1.0× 356 20.5k
Richard S. Finn United States 76 9.0k 0.9× 15.9k 1.8× 8.3k 1.2× 16.3k 3.0× 8.1k 1.6× 370 38.2k
Éric Raymond France 71 8.8k 0.9× 3.1k 0.3× 3.0k 0.4× 10.9k 2.0× 4.4k 0.9× 369 22.4k
Robin Kate Kelley United States 51 3.9k 0.4× 6.1k 0.7× 3.5k 0.5× 6.1k 1.1× 3.0k 0.6× 215 15.4k

Countries citing papers authored by Augusto Villanueva

Since Specialization
Citations

This map shows the geographic impact of Augusto Villanueva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Augusto Villanueva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Augusto Villanueva more than expected).

Fields of papers citing papers by Augusto Villanueva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Augusto Villanueva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Augusto Villanueva. The network helps show where Augusto Villanueva may publish in the future.

Co-authorship network of co-authors of Augusto Villanueva

This figure shows the co-authorship network connecting the top 25 collaborators of Augusto Villanueva. A scholar is included among the top collaborators of Augusto Villanueva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Augusto Villanueva. Augusto Villanueva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Llovet, Josep M., Robin Kate Kelley, Augusto Villanueva, et al.. (2024). Author Correction: Hepatocellular carcinoma. Nature Reviews Disease Primers. 10(1). 10–10. 22 indexed citations
3.
Singal, Amit G., Marco Sanduzzi‐Zamparelli, Pierre Nahon, et al.. (2023). International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance. Journal of Hepatology. 79(1). 226–239. 51 indexed citations
4.
Llovet, Josep M., Amit G. Singal, Augusto Villanueva, et al.. (2022). Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clinical Cancer Research. 28(11). 2297–2305. 13 indexed citations
5.
Gallon, John, Mairene Coto‐Llerena, Caner Ercan, et al.. (2021). Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Molecular Oncology. 16(3). 665–682. 7 indexed citations
6.
Llovet, Josep M., Robin Kate Kelley, Augusto Villanueva, et al.. (2021). Hepatocellular carcinoma. Nature Reviews Disease Primers. 7(1). 6–6. 4089 indexed citations breakdown →
7.
Zoulim, Fabien, Barbara Testoni, Brett A. Miles, et al.. (2021). Landscape of oncoviral genotype and co-infection via human papilloma and hepatitis B viral tumor in situ profiling. iScience. 24(4). 102368–102368. 8 indexed citations
8.
Felden, Johann von, Amanda J. Craig, Teresa García‐Lezana, et al.. (2020). Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene. 40(1). 140–151. 99 indexed citations
9.
Yu, Jia Xin, Amanda J. Craig, Mary E. Duffy, et al.. (2019). Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. Molecular Cancer Therapeutics. 18(9). 1506–1519. 17 indexed citations
10.
Cornell, Liam, Joanne M. Munck, Clara Alsinet, et al.. (2014). DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. Clinical Cancer Research. 21(4). 925–933. 69 indexed citations
11.
Hoshida, Yujin, Augusto Villanueva, Angelo Sangiovanni, et al.. (2013). Prognostic Gene Expression Signature for Patients With Hepatitis C–Related Early-Stage Cirrhosis. Gastroenterology. 144(5). 1024–1030. 158 indexed citations
12.
Lachenmayer, Anja, Clara Alsinet, Radoslav Savić, et al.. (2012). Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. Clinical Cancer Research. 18(18). 4997–5007. 230 indexed citations
13.
Vetter, Diana, Michal Cohen‐Naftaly, Augusto Villanueva, et al.. (2012). Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology. 56(4). 1361–1370. 30 indexed citations
14.
Villanueva, Augusto, Clara Alsinet, Kilangsungla Yanger, et al.. (2012). Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice. Gastroenterology. 143(6). 1660–1669.e7. 248 indexed citations
15.
Villanueva, Augusto, Yujin Hoshida, Carlo Battiston, et al.. (2011). Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. Gastroenterology. 140(5). 1501–1512.e2. 312 indexed citations
16.
Toffanin, Sara, Yujin Hoshida, Anja Lachenmayer, et al.. (2011). MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. Gastroenterology. 140(5). 1618–1628.e16. 171 indexed citations
17.
Villanueva, Augusto & Josep M. Llovet. (2011). Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology. 140(5). 1410–1426. 378 indexed citations breakdown →
18.
Hoshida, Yujin, Sebastian Nijman, Masahiro Kobayashi, et al.. (2009). Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. Cancer Research. 69(18). 7385–7392. 872 indexed citations breakdown →
19.
Ruíz-Tóvar, Jaime, et al.. (2007). Portal Vein Thrombosis After Laparoscopic Splenectomy in Benign Hematologic Diseases. Journal of Laparoendoscopic & Advanced Surgical Techniques. 17(4). 448–454. 10 indexed citations
20.
Lemmer, Eric R., Ying‐Bei Chen, Steven Yea, et al.. (2006). Dysregulation of hedgehog pathway signaling in hepatocellular carcinoma. Cancer Research. 66. 630–630.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jessica Zucman‐Rossi Breakdown of academic impact, for papers by Ann‐Lii Cheng Breakdown of academic impact, for papers by Lewis R. Roberts Breakdown of academic impact, for papers by Irene Oi‐Lin Ng Breakdown of academic impact, for papers by Alejandro Forner Breakdown of academic impact, for papers by Zhao–You Tang Breakdown of academic impact, for papers by Sheung Tat Fan Breakdown of academic impact, for papers by Richard S. Finn Breakdown of academic impact, for papers by Éric Raymond Breakdown of academic impact, for papers by Robin Kate Kelley
Rankless by CCL
2026